(VIANEWS) – Shares of SEQUANA MEDICAL (BEL 20: SEQUA.BR) dropped by a staggering 32.04% in 21 sessions from €4.9 to €3.33 at 20:22 EST on Monday, following the last session’s downward trend. BEL 20 is rising 0.59% to €3,801.81, following the last session’s upward trend.
SEQUANA MEDICAL’s last close was €3.33, 55.6% below its 52-week high of €7.50.
About SEQUANA MEDICAL
Sequana Medical NV develops and commercializes treatment of fluid overload in liver disease, cancer, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Earnings Per Share
As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-0.88.
Revenue Growth
Year-on-year quarterly revenue growth grew by 31.8%, now sitting on 923k for the twelve trailing months.
Moving Average
SEQUANA MEDICAL’s worth is way below its 50-day moving average of €5.12 and way under its 200-day moving average of €5.86.
More news about SEQUANA MEDICAL (SEQUA.BR).
